4
Changes in Ownership
CytomX Therapeutics, Inc. Filed Acc 0001140361-17-003155
Options or other derivatives
- Chief Financial Officer acquired 84,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Goeltz II Robert C. Chief Financial Officer | 2017-01-25 | Grant or award · Stock Option (right to buy) | +84,000 | 84,000 | D: show line 1 in the form |
Loading xslF345X03/doc1.xml…